Causes and consequences of discontinuation of GLP1RAs or tirzepatide
Understanding why people stop taking weight-loss medications reveals opportunities to support long-term treatment success and prevent rapid weight regain.
This Nature Reviews Endocrinology paper comprehensively reviews the growing real-world problem of GLP-1RA and tirzepatide discontinuation, cataloguing reasons (GI side effects, cost, efficacy concerns) and cardiometabolic consequences including weight regain, HbA1c fluctuation, and potential elevated cardiovascular risk. The authors call attention to a 'stop-start cycle' phenomenon with implications for long-term T2DM and obesity management.
What the study was
- Study design
- Comprehensive narrative review
- Population
- T2DM/obesity patients on GLP-1RA or tirzepatide
- Category
- Public Health
- Maturity
- Validated
- Journal
- Nat Rev Endocrinol
Why it surfaced
Nat Rev Endocrinol review on a clinically urgent real-world problem affecting millions on GLP-1 drugs; directly actionable for prescribers; addresses cardiometabolic risk of incomplete adherence.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.